These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 10416524)

  • 1. Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens.
    Hall CS; Raines CP; Barnett SH; Moore RD; Gallant JE
    AIDS; 1999 Jul; 13(10):1207-12. PubMed ID: 10416524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
    Casado JL; Dronda F; Hertogs K; Sabido R; Antela A; Martí-Belda P; Dehertogh P; Moreno S;
    AIDS Res Hum Retroviruses; 2001 Jan; 17(2):93-8. PubMed ID: 11177388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure.
    Deeks SG; Grant RM; Beatty GW; Horton C; Detmer J; Eastman S
    AIDS; 1998 Jul; 12(10):F97-102. PubMed ID: 9677159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir.
    Tebas P; Patick AK; Kane EM; Klebert MK; Simpson JH; Erice A; Powderly WG; Henry K
    AIDS; 1999 Feb; 13(2):F23-8. PubMed ID: 10202820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
    Piketty C; Race E; Castiel P; Belec L; Peytavin G; Si-Mohamed A; Gonzalez-Canali G; Weiss L; Clavel F; Kazatchkine MD
    AIDS; 1999 Jul; 13(11):F71-7. PubMed ID: 10449277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of nelfinavir in patients switched from ritonavir/saquinavir combination antiretroviral therapy.
    Hellinger JA; Cohen CJ; Stein AJ; Gallant JE; Gathe J; Keiser P
    HIV Clin Trials; 2000; 1(2):25-8. PubMed ID: 11590495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic response.
    Paredes R; Puig T; Arnó A; Negredo E; Balagué M; Bonjoch A; Jou A; Tuldrà A; Tural C; Sirera G; Veny A; Romeu J; Ruiz L; Clotet B
    J Acquir Immune Defic Syndr; 1999 Oct; 22(2):132-8. PubMed ID: 10843526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients.
    Fätkenheuer G; Theisen A; Rockstroh J; Grabow T; Wicke C; Becker K; Wieland U; Pfister H; Reiser M; Hegener P; Franzen C; Schwenk A; Salzberger B
    AIDS; 1997 Nov; 11(14):F113-6. PubMed ID: 9386799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of ritonavir plus saquinavir- and nelfinavir plus saquinavir-containing regimens as salvage therapy in children with human immunodeficiency type 1 infection.
    Hoffmann F; Notheis G; Wintergerst U; Eberle J; Gürtler L; Belohradsky BH
    Pediatr Infect Dis J; 2000 Jan; 19(1):47-51. PubMed ID: 10643850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage therapy with regimens containing ritonavir and saquinavir in extensively pretreated HIV-infected patients.
    Fätkenheuer G; Hoetelmans RM; Hunn N; Schwenk A; Franzen C; Reiser M; Jütte A; Rockstroh J; Diehl V; Salzberger B
    AIDS; 1999 Aug; 13(12):1485-9. PubMed ID: 10465071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome.
    Deeks SG; Hellmann NS; Grant RM; Parkin NT; Petropoulos CJ; Becker M; Symonds W; Chesney M; Volberding PA
    J Infect Dis; 1999 Jun; 179(6):1375-81. PubMed ID: 10228057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial.
    Kirk O; Katzenstein TL; Gerstoft J; Mathiesen L; Nielsen H; Pedersen C; Lundgren JD
    AIDS; 1999 Jan; 13(1):F9-16. PubMed ID: 10207539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized salvage therapy with saquinavir-ritonavir versus saquinavir-nelfinavir for highly protease inhibitor-experienced HIV-infected patients.
    Chavanet P; Piroth L; Grappin M; Buisson M; Gourdon F; Cabié A; Duong M; Brunel-Dalmas F; Peytavin G; Portier H
    HIV Clin Trials; 2001; 2(5):408-12. PubMed ID: 11673815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
    Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
    Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety and antiviral effect of protease inhibitors in children.
    Temple ME; Koranyi KI; Nahata MC
    Pharmacotherapy; 2001 Mar; 21(3):287-94. PubMed ID: 11253853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
    Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S
    AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of a second-line protease inhibitor-containing regimen in patients failing or intolerant of a first highly active antiretroviral therapy.
    Bini T; Testa L; Chiesa E; Adorni F; Abeli C; Castelnuovo B; Melzi S; Sollima S; Bongiovanni M; d'Arminio Monforte A
    J Acquir Immune Defic Syndr; 2000 Jun; 24(2):115-22. PubMed ID: 10935686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia.
    Deeks SG; Barbour JD; Grant RM; Martin JN
    AIDS; 2002 Jan; 16(2):201-7. PubMed ID: 11807304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy.
    Deeks SG; Hecht FM; Swanson M; Elbeik T; Loftus R; Cohen PT; Grant RM
    AIDS; 1999 Apr; 13(6):F35-43. PubMed ID: 10397555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
    Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
    JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.